Menu

CanRIO Recommendations for the Assessment and Management of Rheumatic Immune Related Adverse Events from Cancer Immunotherapy

Coming 2021! With support from the Canadian Rheumatology Association (CRA) Guidelines Committee, CanRIO has assembled a working group of rheumatologists, oncologist and patient representative to present a Canadian perspective on the assessment and management of rheumatic immune related adverse events from cancer immunotherapy as well as patients with pre-existing autoimmune disease and cancer, for which immunotherapy is indicated.